← Back to Search

Beta Blocker

Topical 0.5% Timolol for Placental Chorioangioma

Phase < 1
Waitlist Available
Led By Alfons L. Krol, M.D.
Research Sponsored by Oregon Health and Science University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Infants 1 month to 8 months of age with infantile hemangioma (IH) that are 3 cm or less on the scalp, trunk, or extremities.
Be younger than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up at 6 months
Awards & highlights
All Individual Drugs Already Approved

Summary

The purpose of this study is to learn about a new potential use for topical timolol 0.5% aqueous solution that may help treat small uncomplicated infantile hemangiomas. This study would examine whether topical timolol could be a potential therapy.

Eligible Conditions
  • Placental Chorioangioma
  • Hemangioma
  • Infants

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~at 6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and at 6 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Proportion of Subjects in Treatment Group Compared to Placebo Group With at Least 75% Improvement in the Extent of the Hemangioma as Compared to Baseline Photos.
Secondary study objectives
Compare Treatment Group to Control Group Improvement Assessments

Awards & Highlights

All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.

Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: Topical 0.5% TimololActive Control1 Intervention
Half of the enrolled subjects (intervention group) will receive topical 0.5% Timolol.
Group II: PlaceboPlacebo Group1 Intervention
Aqueous placebo, 2-3 drops to cover the hemangioma, twice daily

Find a Location

Who is running the clinical trial?

Oregon Health and Science UniversityLead Sponsor
1,006 Previous Clinical Trials
7,413,966 Total Patients Enrolled
Alfons L. Krol, M.D.Principal InvestigatorOregon Health and Science University
~0 spots leftby Nov 2025